- Targeting IDH|Mutant Glioma🔍
- A new era for glioma therapy — targeting mutant IDH🔍
- Therapies for IDH|Mutant Gliomas🔍
- Targeting IDH in Low|Grade Glioma🔍
- Treatment of IDH|mutant glioma in the INDIGO era🔍
- FDA Approves Drug for Low|Grade Glioma With IDH Gene Mutation🔍
- Targeting Mutant IDH to Treat Low|grade Glioma🔍
- Isocitrate dehydrogenase mutations in gliomas🔍
Targeting IDH|Mutant Glioma
Targeting IDH-Mutant Glioma - PMC
Telomere maintenance mechanisms offer another potential target for IDH-mutant gliomas. Nearly all oligodendrogliomas, with both IDH-mutation and ...
A new era for glioma therapy — targeting mutant IDH - Nature
A new era for glioma therapy — targeting mutant IDH ... Hotspot point mutations in IDH1 occur in the vast majority of adult grade 2–3 gliomas. The ...
Therapies for IDH-Mutant Gliomas - PMC - PubMed Central
... Glioma, Oligodendroglioma, Astrocytoma, IDH mutations, IDH ... targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
Targeting IDH in Low-Grade Glioma
Schiff D. Headway against brain tumors with molecular targeting of IDH-mutant gliomas. N Engl J Med 2023;389:653-654. Go ...
Treatment of IDH-mutant glioma in the INDIGO era - Nature
... mutant IDH inhibitor treatment in IDH-mutant gliomas responsive to mutant IDH ... A vaccine targeting mutant IDH1 in newly diagnosed glioma.
FDA Approves Drug for Low-Grade Glioma With IDH Gene Mutation
The drug, vorasidenib, targets a mutation in IDH genes, which are present in 80% of low-grade gliomas. IDH-mutant gliomas make up about 20 ...
Targeting Mutant IDH to Treat Low-grade Glioma - touchONCOLOGY
INDIGO trial: Vorasidenib in IDH-mutant LGG. An approach to treat LGG by targeting the tumour-specific mutation in the IDH1 and IDH2 genes has ...
Isocitrate dehydrogenase mutations in gliomas: A review of current ...
In this review, we highlight current techniques targeting IDH-mutated gliomas and summarize current and completed clinical trials exploring these strategies.
Vorasidenib Is Effective against Low-Grade Gliomas - NCI
Unlike other drugs that target mutant IDH proteins, this one can cross the blood-brain barrier. The study's ability to recruit more than 300 ...
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
The INDIGO trial was a phase 3 clinical trial with a molecularly targeted therapy for IDH-mutant glioma. Molecularly targeted therapies have the ...
New Clinical Trial Tests a Kind of Precision Medicine Treatment for ...
Yet, according to Dr. Wu's preclinical laboratory researchExit Disclaimer, these mutations also make IDH-mutant gliomas uniquely vulnerable to ...
Support: No funding was received in the publication of this article. Targeting Mutant IDH to Treat Low- grade Glioma. Katherine B Peters.
Mutant IDH in Gliomas: Role in Cancer and Treatment Options - MDPI
Isocitrate dehydrogenase (IDH) is the most mutated metabolic gene in human cancer. Mutations in this gene have been identified in a high percentage of ...
IDH Mutation in Glioma: New Insights and Promises for the Future
Second, IDH1/2 mutations occur at an early stage of tumorigenesis and, in fact, are thought to be the initiating mutation in IDH-mutant low- ...
IDH Mutations in Glioma: Double-Edged Sword in Clinical ... - MDPI
Therefore, exploiting the weaknesses of IDH-mutant gliomas and targeting ... Effective immuno-targeting of the IDH1 mutation R132H in a murine model of ...
Isocitrate dehydrogenase mutation as a therapeutic target in gliomas
IDH mutations have been suggested as an important early event in tumorigenesis. Large scale genomic analyses of IDH-mutant gliomas found that IDH1 mutation ...
Implications of IDH Mutations for Success of Glioma Immunotherapy
Hence, there are questions about how well IDH-mutant glioma will respond to immunotherapy, even though the mutations themselves are ...
Targeting therapeutic vulnerabilities with PARP inhibition and ...
One strategy to treat IDHmut tumors is to inhibit the mutant IDH protein and 2-HG production. This is being tested in IDH-mutated cancers.
Genotype-targeted local therapy of glioma - PNAS
... target IDH1 mutant gliomas (8–11). ... Formulation of Sustained Release Microparticles of Metabolic Inhibitors Targeting IDH Mutant Glioma.
Isocitrate Dehydrogenase Mutations in Glioma - Frontiers
... IDH mutant gliomas and recurrent gliomas ... Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.